Table 4. CAP2 expression in cancers.

Cancer	cancer subtype	p-value	fold change	rank (%)	sample	reference
Bladder	Superficial Bladder cancer	2E–15	−7.061	3	76	[41]
	Superficial Bladder cancer	2.79E–15	−2.41	4	194	[41]
	Infiltrating Bladder Urothelial Carcinoma	9.95E–15	−4.549	5	129	[42]
Brain	Glioblastoma	4.70E–17	−7.893	1	31	[43]
	Brain Glioblastoma	1.87E–22	−5.558	1	552	TCGA
	Glioblastoma	8.42E–12	−3.522	2	25	[42]
	Glioblastoma	2.90E–6	−4.275	3	84	[44]
	Oligodendroglioma	3.58E–7	−3.842	6	42	[45]
Breast	Invasive Ductal Breast Carcinoma Epithelia	7.92E–6	2.074	1	23	[46]
Colorectal	Colon Carcinoma	5.13E–8	2.038	5	15	[47]
	Colorectal Adenocarcinoma	1.30E–6	−2.125	7	69	[47]
Esophageal	Barrett's Esophagus	7.38E–9	−2.728	8	43	[48]
	Esophageal Adenocarcinoma	1.26E–11	−2.124	9	103	[48]
Gastric	Diffuse Gastric Adenocarcinoma	1.73E–5	4.120	1	37	[49]
	Gastric Mixed Adenocarcinoma	1.43E–6	3.077	2	35	[49]
Kidney	Clear Cell Renal Cell Carcinoma	1.67E–6	3.098	5	31	[50]
	Papillary Renal Cell Carcinoma	4.18E–5	2.459	3	5	[50]
Leukemia	Pro-B Acute Lymphoblastic Leukemia	8.93E–16	2.209	8	144	[51]
Liver	Hepatocellular Carcinoma	3.27E–99	5.790	1	445	[52]
	Hepatocellular Carcinoma	2.26E–13	8.569	1	45	[53]
	Liver Cell Dysplasia	9.81E–5	2.140	1	27	[53]
	Hepatocellular Carcinoma	1.41E–28	3.526	1	179	[54]
	Hepatocellular Carcinoma	2.92E–10	4.254	1	43	[52]
Lung	Squamous Cell Lung Carcinoma	1.27E–6	−4.154	8	62	[29]
Melanoma	Cutaneous Melanoma	2.03E–9	3.743	3	52	[55]
	Benign Melanocytic Skin Nevus	3.50E–5	−2.859	3	25	[55]
Ovarian	Ovarian Serous Adenocarcinoma	1.44E–8	−3.384	7	53	[56]
Prostate	Prostate Carcinoma	5.86E–6	−2.238	2	34	[57]
sarcoma	Myxofibrosarcoma	5.56E–5	−3.711	10	40	[58]
Other	Teratoma, NOS	1.16E–7	2.689	5	20	[59]
	Yolk Sac Tumor, NOS	3.18E–6	2.342	4	15	[59]
	Vulvar Intraepithelial Neoplasia	2.24E–6	−2.809	1	19	[60]